Citius Pharmaceuticals, INC. (CTXR) — 8-K Filings

All 8-K filings from Citius Pharmaceuticals, INC.. Browse 38 Current Event Report reports with AI-powered summaries and risk analysis.

8-K Filings (38)

8-K Filing — Apr 6, 2026
8-K Filing — Dec 1, 2025
Citius Pharmaceuticals Files 8-K — Oct 23, 2025 Risk: low
Citius Pharmaceuticals, Inc. filed an 8-K on October 23, 2025, reporting on Regulation FD Disclosure and Financial Statements and Exhibits. The company, incorpo
Citius Pharmaceuticals Files 8-K — Oct 21, 2025 Risk: medium
On October 20, 2025, Citius Pharmaceuticals, Inc. entered into a material definitive agreement. The company also reported other events and filed financial state
Citius Pharmaceuticals Files 8-K — Jul 8, 2025 Risk: low
Citius Pharmaceuticals, Inc. filed an 8-K on July 8, 2025, reporting on other events and financial statements/exhibits. The filing date is July 8, 2025, with th
Citius Pharmaceuticals Enters Material Definitive Agreement — Jun 12, 2025 Risk: medium
Citius Pharmaceuticals, Inc. announced on June 9, 2025, the entry into a material definitive agreement. The company, incorporated in Nevada, filed an 8-K report
Citius Pharma Files 8-K on Security Holder Rights & Bylaws — Jun 9, 2025 Risk: medium
Citius Pharmaceuticals, Inc. filed an 8-K on June 9, 2025, reporting on several items including material modifications to security holder rights, amendments to
Citius Pharmaceuticals Enters Material Definitive Agreement — Jun 3, 2025 Risk: medium
Citius Pharmaceuticals, Inc. announced on June 2, 2025, that it has entered into a material definitive agreement. This agreement creates a direct financial obli
Citius Pharmaceuticals Faces Delisting Notice — May 30, 2025 Risk: high
Citius Pharmaceuticals, Inc. filed an 8-K on May 29, 2025, to report a notice of delisting or failure to satisfy a continued listing rule. The company, incorpor
Citius Pharmaceuticals Files 8-K: Agreements, Equity Sales, Bylaw Changes — Apr 18, 2025 Risk: medium
On April 16, 2025, Citius Pharmaceuticals, Inc. entered into a material definitive agreement. The company also reported on unregistered sales of equity securiti
Citius Pharmaceuticals Enters Material Definitive Agreement — Apr 3, 2025 Risk: medium
Citius Pharmaceuticals, Inc. announced on March 28, 2025, that it entered into a material definitive agreement. The filing does not provide specific details abo
Citius Pharmaceuticals Enters Material Definitive Agreement — Apr 2, 2025 Risk: medium
Citius Pharmaceuticals, Inc. announced on April 1, 2025, that it has entered into a material definitive agreement. The company, incorporated in Nevada, is invol
Citius Pharma Files 8-K on Shareholder Votes — Mar 10, 2025 Risk: low
Citius Pharmaceuticals, Inc. filed an 8-K on March 10, 2025, to report on matters submitted to a vote of its security holders. The filing details the company's
Citius Pharmaceuticals Files 8-K — Feb 6, 2025 Risk: low
Citius Pharmaceuticals, Inc. filed an 8-K on February 6, 2025, reporting other events and financial statements. The company, incorporated in Nevada, has its pri
Citius Pharmaceuticals Files 8-K — Jan 8, 2025 Risk: medium
On January 7, 2025, Citius Pharmaceuticals, Inc. entered into a material definitive agreement. The company also reported other events and filed financial statem
Citius Pharmaceuticals Files 8-K with Exhibits — Jan 7, 2025 Risk: low
On January 7, 2025, Citius Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns the submission of financial statements and exhibits, with no
Citius Pharmaceuticals Files 8-K on Financials — Dec 27, 2024 Risk: low
Citius Pharmaceuticals, Inc. filed an 8-K on December 27, 2024, reporting on its results of operations and financial condition. The filing also includes financi
Citius Pharma Sells Mino-Lok to NovaBay for $10M Upfront — Dec 20, 2024 Risk: medium
Citius Pharmaceuticals, Inc. announced on December 18, 2024, that it has entered into a definitive agreement to sell its Mino-Lok® product candidate to NovaBay
Citius Pharmaceuticals Files 8-K on Security Holder Rights — Nov 26, 2024 Risk: medium
Citius Pharmaceuticals, Inc. filed an 8-K on November 25, 2024, reporting material modifications to the rights of security holders and other events. The filing
Citius Pharmaceuticals Files 8-K — Nov 25, 2024 Risk: low
Citius Pharmaceuticals, Inc. filed an 8-K on November 25, 2024, reporting other events and financial statements. The filing does not contain specific details ab
Citius Pharmaceuticals Files 8-K: Material Agreement Announced — Nov 18, 2024 Risk: medium
Citius Pharmaceuticals, Inc. announced on November 15, 2024, that it has entered into a material definitive agreement. The company also reported other events an
Citius Pharma Faces Nasdaq Delisting Risk — Nov 13, 2024 Risk: high
Citius Pharmaceuticals, Inc. announced on November 6, 2024, that it received a notification from the Nasdaq Stock Market indicating a failure to meet the minimu
Citius Pharmaceuticals Files 8-K — Nov 12, 2024 Risk: medium
Citius Pharmaceuticals, Inc. filed an 8-K on November 12, 2024, reporting "Other Events" and "Financial Statements and Exhibits" as of November 11, 2024. The fi
Citius Pharma Enters Material Definitive Agreement — Sep 27, 2024 Risk: medium
Citius Pharmaceuticals, Inc. announced on September 25, 2024, that it entered into a material definitive agreement. The filing does not disclose specific detail
Citius Pharmaceuticals Enters Material Definitive Agreement — Sep 13, 2024 Risk: medium
Citius Pharmaceuticals, Inc. announced on September 9, 2024, that it entered into a material definitive agreement. The filing does not disclose specific details
Citius Pharma Faces Nasdaq Delisting Warning — Sep 11, 2024 Risk: medium
Citius Pharmaceuticals, Inc. announced on September 10, 2024, that it received a notification from the Nasdaq Stock Market regarding its failure to meet the min
Citius Pharmaceuticals Files 8-K — Sep 5, 2024 Risk: low
Citius Pharmaceuticals, Inc. filed an 8-K on September 5, 2024, reporting other events and financial statements. The company, incorporated in Nevada, has its pr
Citius Pharma Secures Loan Agreement with Innoviva — Aug 16, 2024 Risk: medium
On August 12, 2024, Citius Pharmaceuticals, Inc. entered into a Material Definitive Agreement, specifically a Loan and Security Agreement with Innoviva, Inc. Th
Citius Pharmaceuticals Files 8-K — Aug 8, 2024 Risk: low
Citius Pharmaceuticals, Inc. filed an 8-K on August 8, 2024, to report other events and financial statements. The filing does not contain specific details about
Citius Pharmaceuticals Files 8-K — May 21, 2024 Risk: low
Citius Pharmaceuticals, Inc. filed an 8-K on May 21, 2024, to report other events and financial statements. The filing does not contain specific details about n
Citius Pharmaceuticals Files 8-K, Enters Material Agreement — Apr 30, 2024 Risk: medium
On April 25, 2024, Citius Pharmaceuticals, Inc. entered into a material definitive agreement, the details of which are not fully disclosed in this filing. The c
Citius Pharma to Acquire NovaLead Pharma for $15M — Apr 5, 2024 Risk: medium
Citius Pharmaceuticals, Inc. announced on April 3, 2024, that it has entered into a definitive agreement to acquire all outstanding shares of NovaLead Pharma Lt
Citius Pharmaceuticals Files 8-K — Mar 18, 2024 Risk: low
Citius Pharmaceuticals, Inc. filed an 8-K on March 18, 2024, to report other events and financial statements. The filing does not contain specific financial fig
Citius Pharmaceuticals Faces Delisting Concerns — Mar 13, 2024 Risk: high
Citius Pharmaceuticals, Inc. filed an 8-K on March 12, 2024, to report a notice of delisting or failure to satisfy a continued listing rule. The company also su
Citius Pharma Files 8-K on Financial Condition and Operations — Feb 15, 2024 Risk: low
Citius Pharmaceuticals, Inc. filed an 8-K on February 15, 2024, reporting an event that occurred on February 14, 2024. The filing, under Commission File Number
Citius Pharma Files 8-K on 'Other Events' & Financial Exhibits — Jan 23, 2024
Citius Pharmaceuticals, Inc. filed an 8-K on January 23, 2024, to report an 'Other Event' and 'Financial Statements and Exhibits.' This filing indicates that th
Citius Pharma Adopts Shareholder Proxy Access for Director Nominations — Jan 5, 2024
Citius Pharmaceuticals, Inc. filed an 8-K on January 4, 2024, to announce that it will allow shareholders to nominate directors for its board using the company'
Citius Pharma Files 8-K, Confirms Nasdaq Listing for CTXR — Jan 2, 2024
Citius Pharmaceuticals, Inc. filed an 8-K on January 2, 2024, to report on its operations and financial condition, specifically noting its common stock, $0.001

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX